Verici Dx is targeting cash-flow breakeven by the end of 2027 as demand for its kidney transplant diagnostic test, Tutivia, continues to grow.
Tutivia generated revenue of $1.8 million in the first half of 2026, compared with $1.2 million in the same period last year. Orders increased by approximately 52% year-on-year in the third quarter, with the company now serving 36 active US transplant centres.
Average reimbursement remained approximately $2,300 per test.
Verici is targeting Tutivia revenue of $4.75 million for 2026. The company is expanding its commercial team and increasing marketing activity to drive adoption across additional transplant centres.
In October, Verici completed an £8.75 million fundraising to support sales expansion, laboratory investment and working capital.
Management expects the funding to provide sufficient resources to support its growth plans and reach cash-flow breakeven by the end of 2027, based on current projections.
The company is also progressing its product pipeline. TranscripTx is scheduled for launch in the fourth quarter of 2026, while development continues on Protega and its pre-transplant rejection assessment test, PTRA.
Verici’s strategy centres on increasing Tutivia sales while introducing additional diagnostic products to the kidney transplant market.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
